XOMA Royalty (XOMA) EBITDA (2011 - 2026)
XOMA Royalty's (XOMA) quarterly EBITDA came in at -$477000.0 in Q1 2026, down 108.04% year-on-year from $5.9 million in Q1 2025, and up 81.06% quarter-over-quarter from -$2.5 million in Q4 2025.
XOMA Royalty (XOMA) EBITDA (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed EBITDA across 16 years of filings, most recently posting -$477000.0 for Q1 2026.
- EBITDA for Q1 2026 came in at -$477000.0, down 108.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $283000.0 (up 129.15% YoY), and the FY2025 annual result was $6.7 million, up 116.74% from the prior year.
- EBITDA came in at -$477000.0 for Q1 2026 at XOMA Royalty, up from -$2.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $16.0 million in Q2 2024 to a low of -$20.1 million in Q4 2023.
- The 5-year median for EBITDA is -$4.7 million (2022), against an average of -$4.0 million.
- Across the five-year window, EBITDA sank 330.39% in 2023 and surged 396.02% in 2024, its largest moves.
- XOMA Royalty's EBITDA stood at -$6.0 million in 2022, then slumped by 236.5% to -$20.1 million in 2023, then surged by 63.94% to -$7.3 million in 2024, then jumped by 65.27% to -$2.5 million in 2025, then jumped by 81.06% to -$477000.0 in 2026.
- The last three EBITDA figures came in at -$477000.0 (Q1 2026), -$2.5 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.57 Mn | - | -477,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -477,000.00 |
| Dec 31, 2025 | -2.52 Mn |
| Sep 30, 2025 | -1.33 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | -7.25 Mn |
| Sep 30, 2024 | -15.64 Mn |
| Jun 30, 2024 | 15.99 Mn |
| Mar 31, 2024 | -8.60 Mn |
| Dec 31, 2023 | -20.11 Mn |
| Sep 30, 2023 | -5.51 Mn |
| Jun 30, 2023 | -5.40 Mn |
| Mar 31, 2023 | -9.81 Mn |
| Dec 31, 2022 | -5.98 Mn |
| Sep 30, 2022 | -4.18 Mn |
| Jun 30, 2022 | -4.67 Mn |
| Mar 31, 2022 | -2.28 Mn |
| Dec 31, 2021 | 29.84 Mn |
| Sep 30, 2021 | -4.44 Mn |
| Jun 30, 2021 | -2.24 Mn |